Gabriele Fischer

Prof. Dr. Gabriele Fischer

Center for Public Health, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2006 in Addiction
Verified
Journal Article
Closed access
PDF file
GFGabriele Fischer
Gabriele Fischer
RORomana Ortner
Romana Ortner
KRKlaudia Rohrmeister
Klaudia Rohrmeister
RJReinhold Jagsch
Reinhold Jagsch
ABAndjela Baewert
Andjela Baewert
HAHarald Aschauer
Harald Aschauer

7 August 2008 in Addiction
Verified
Journal Article
Closed access
PDF file
BWBernadette Winklbaur
Bernadette Winklbaur
NKNina Kopf
Nina Kopf
NENina Ebner
Nina Ebner
EJErika Jung
Erika Jung
KTKenneth Thau
Kenneth Thau
GFGabriele Fischer
Gabriele Fischer

1 April 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
KKKarol Kaltenbach
Karol Kaltenbach
KOKevin E. O’gRady
Kevin E. O’gRady
SHSarah H. Heil
Sarah H. Heil
ASAmy L. Salisbury
Amy L. Salisbury
MCMara Coyle
Mara Coyle
HJHendrée E. Jones
Hendrée E. Jones
Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy. However, the literature on the relationship between longer-term effects of prenatal exposure to these medications and childhood development is both spare and inconsistent. Participants were 96 children and their mothers who participated in MOTHER, a randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present study examined child growth parameters, cognition, language abilities, sensory processing, and temperament from 0 to 36 months of the child's life. Maternal perceptions of parenting stress, home environment, and addiction severity were also examined. Tests of mean differences between children prenatally exposed to methadone vs. buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly, tests of mean differences between children treated for NAS relative to those not treated for NAS yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including expected child increases in weight, head and height, and overall gains in cognitive development, language abilities, sensory processing, and temperament. For mothers, significant changes over time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably seen in increasing parenting stress, but also an increasingly enriched home environment (4/7 scales) CONCLUSIONS: Findings strongly suggest no deleterious effects of buprenorphine relative to methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive development, language abilities, sensory processing, and temperament. Moreover, findings suggest that prenatal opioid agonist exposure is not deleterious to normal physical and mental development.

31 March 2006 in Dialogues in clinical neuroscience
Verified
Journal Article
Open access
BWBernadette Winklbaur
Bernadette Winklbaur
NENina Ebner
Nina Ebner
GSGabriele Sachs
Gabriele Sachs
KTKenneth Thau
Kenneth Thau
GFGabriele Fischer
Gabriele Fischer
The comorbidity of schizophrenia and substance abuse has attracted increasing attention in the past years, with multiple potential links, including genetic vulnerability, neurobiological aspects, side effects of medications, and psychosocial factors being under discussion. The link between the use o …

15 June 2005 in Addiction
Verified
Journal Article
Closed access
PDF file
HEHarald Eder
Harald Eder
RJReinhold Jagsch
Reinhold Jagsch
DKDominik Kraigher
Dominik Kraigher
APAndjela Primorac
Andjela Primorac
NENina Ebner
Nina Ebner
GFGabriele Fischer
Gabriele Fischer

16 April 2010 in Journal of Addictive Diseases
Verified
Journal Article
Closed access
AUAnnemarie Unger
Annemarie Unger
EJErika Jung
Erika Jung
BWBernadette Winklbaur
Bernadette Winklbaur
GFGabriele Fischer
Gabriele Fischer
Gender, a biological determinant of mental health and illness, plays a critical role in determining patients' susceptibility, exposure to mental health risks, and related outcomes. Regarding sex differences in the epidemiology of opioid dependence, one third of the patients are women of childbearing age. Women have an earlier age of initiation of substance use and a more rapid progression to drug involvement and dependence than men. Generally few studies exist which focus on the special needs of women in opioid maintenance therapy. The aim of this paper is to provide an overview of treatment options for opioid-dependent women, with a special focus on buprenorphine, and to look at recent findings related to other factors that should be taken into consideration in optimizing the treatment of opioid-dependent women. Issues addressed include the role of gender in the choice of medication assisted treatment, sex differences in pharmacodynamics and pharmacokinetics of buprenorphine drug interactions, cardiac interactions, induction of buprenorphine in pregnant patients, the neonatal abstinence syndrome and breastfeeding. This paper aims to heighten the awareness for the need to take gender into consideration when making treatment decisions in an effort to optimize services and enhance the quality of life of women suffering from substance abuse.